The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 915-922

  Matsui, Taka Aki ^a   Sowa, Yoshihiro ^a   Murata, Hiroaki ^a   Takagi, Koichi ^a   Nakanishi, Ryoko ^a   Aoki, Shunji ^b   Yoshikawa, Masayuki ^c   Kobayashi, Motomasa ^b   Sakabe, Tomoya ^a   Kubo, Toshikazu ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cell cycle arrest; Cryptolepine; Osteosarcoma; Sp1

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOLEPINE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA TOPOISOMERASE (ATP HYDROLYSING); INDOLE ALKALOID; LUCIFERASE; MESSENGER RNA; PROTEIN P53; QUINOLINE DERIVATIVE; TRANSCRIPTION FACTOR SP1;

ADENOCARCINOMA; ARTICLE; BONE TUMOR; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL PROLIFERATION; COLON TUMOR; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PROMOTER REGION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BONE NEOPLASMS; CELL DIVISION; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA TOPOISOMERASES, TYPE II; ELECTROPHORETIC MOBILITY SHIFT ASSAY; G2 PHASE; HUMANS; INDOLE ALKALOIDS; LUCIFERASES; OSTEOSARCOMA; PROMOTER REGIONS (GENETICS); QUINOLINES; RESPONSE ELEMENTS; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35848958824     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.915     Document Type: Article

References (34)

1. Unni KK: Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases. 5th Edition, Lippincott-Raven, Philadelphia, pp143-183, 1996.
2. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10: 5-15, 1992.
3. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, Rouesse J, Spooner D, Craft AW, Somers R, Pringle J, Malcolm AJ, Eijken J, Thomas D, Uscinska B, Machin D and Glabbeke M: A comparision of two short intensive adjuvant chemotherapy regimens in operable osteo-sarcima of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10: 1579-1591, 1992. (Pubitemid 23057988)
4. Patel SJ, Lynch JW Jr, Jhonson T, Carroll RR, Schumacher C, Spanier S and Scarborough M: Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 25: 489-495, 2002.
5. Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ and Antman K: Adjuvant therapy of osteosarcoma-A phase II trial: Southwest Oncology Group Study 9139. Cancer 100: 818-825, 2004. (Pubitemid 38176862)
6. Marina NM, Pratt CB, Rao BN, Shema SJ and Meyer WH: Improved prognosis of children with osteosarcoma matastatic to the lung(s) at the time of diagnosis. Cancer 70: 2722-2727, 1992.
7. Voute PA, Souhami RL, Nooij M, Somers R, Cortes-Funes H, van der Eijken JW, Pringle J, Hogendoorn PC, Kirkpatrick A, Uscinska BM, van Glabbeke M, Machin D and Weeden S: A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 10: 1211-1218, 1999.
8. Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jurgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W and Bielack SS: Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21: 334-341, 2003.
9. Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, Manfrini M and Galletti S: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14: 1126-1134, 2003.
10. Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R and Benjamin RS: A phase II study of cisplatin, doxorubicin and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101: 156-163, 2004. (Pubitemid 38812435)
11. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma: p-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 78A: 366-375, 1996.
12. Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y and Ashihara T: Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res 21: 317-320, 2001.
13. 1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
14. 1 arrest. Cell 76: 1013-1023, 1994.
15. 2/M arrest after DNA damage. J Biol Chem 276: 42971-42977, 2001.
16. 2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25: 3364-3387, 2005.
17. 3. Cancer Lett 129: 61-68, 1998.
18. Gartel AL, Serfas MS and Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213: 138-149, 1996.
19. Toguchida J, Yamaguchi T, Ritchie B, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-6199, 1992.
20. Lowe SW, Ruley HE, Jacks T and Housman DE: p53 dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74: 957-967, 1993. (Pubitemid 23289454)
21. Wang LH, Okaichi K, Ihara M and Okumura Y: Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point. Anticancer Res 18: 321-325, 1998. (Pubitemid 28174726)
22. EL-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
23. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H and Sakai T: Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206, 1997.
24. Gellert E, Hamet R and Schlittler E: Die Konstitution des Alkaloids Cryptolepin. Helv Chim Acta 34: 642-651, 1951.
25. Gunatilaka AAL, Sotheeswaran S, Balasubramaniam S, Chandrasekara AI and Sriyani HTB: Studies on medicinal plants of Sri Lanka. III. Pharmacologically important alkaloids of some sida species. Planta Med 39: 66-72, 1980.
26. Kirby GC, Paine A and Warhurst DC: In vitro and in vivo anti-malarial activity of cryptolepine, a plant-derived indoloquinoline. Phytother Res 9: 359-363, 1995.
27. Dassonneville L, Lansiaux A, Wattelet A, Wattez N, Mahieu C, van Miert S, Pieters L and Bailly C: Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur J Pharmacol 409: 9-18, 2000.
28. Bonjean K, De Pauw-Gillet MC, Defresne MP, Colson P, Houssier C, Dassonneville L, Bailly C, Greimers R, Wright C, Quetin-Leclercq J, Tits M and Angenot L: The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry 37: 5136-5146, 1998.
29. Dassonneville L, Bonjean K, De Pauw-Gillet MC, Colson P, Houssier C, Quetin-Leclercq J, Angenot L and Bailly C: Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: cryptolepine, matadine, and serpentine. Biochemistry 38: 7719-7726, 1999. (Pubitemid 129515078)
30. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997. (Pubitemid 28033553)
31. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H and Sakai T: Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 59: 4266-4270, 1999.
32. WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
33. Waf1/Cip1 regulation by transforming growth factor-β. J Biol Chem 275: 29244-29256, 2000.
34. Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A and Kobayashi M: Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun 342: 101-106, 2006.